Serum pseudouridine as a biochemical marker in small cell lung cancer
1
S29 lin, D-10OOEerlin 39. Prax Klin Pneumol 1987;4l(Spec no):754-5. Basing on the favourable results obtained with palliative-sympto- matic obliteration (pleurodesis) of malignant pleural effusions with tetracycline hydrochloride, we also used this therapy in 18 cases of malignant pericardial effusions - mostly caused by pleuropulmonary tumors. In 16 patients (88%) it was possible to stop the exudation within 2-l 1 days without recurrence during follow-up treatment. Since no complications worth mentioning were seen, we can consider drainage and intrapericardial instillation of tetracycline as the presently best possible method in the palliative treatment of this tumor complication. Flare responses in small cell carcinoma of the lung. Cosolo W, Morstyn G, Arkles B, Zimet AS, Zalcberg JR. Deparfmenf ofMedical Oncology, Reparriation General Hospital, Wesr Heidelberg, Vie. 3081. Clin Nucl Med 1988;13:13-6. Two cases of small cell carcinoma of the lung in which flare responses were demonstrated are discussed. Although the primary tumor and extraskeletal metastases responded to fist-line chemotherapy, bone scintigraphs performed 3 months after the start of treatment suggested tumor progression. Howcvcr, following repeat bone imaging and sub- sequent clinical evaluation, the interim scintigraphs appeared to repre- sent an unusual flare response, in which the activity of pre-existing hot spots increased and new lesions developed. Scintigraphic diagnosis of rib lesions in patients with lung carci- noma. Matsumoto S. Shibuya H, Umchara I, Suzuki S. DepurfmenlofRadiol- ogy, TokyoMedicalandDental Universily. Bunkyo-ku, Tokyo 113. Clin Nucl Med 1987;12:960-2. One hundred twenty-five patients with carcinoma of the lung re- ceived 17 1 pyrophosphate bone scans. Twenty-three ( 18%) of these 125 patients had abnormal uptake only in the ribs. Of these 23 patients, 14 (61%) were diagnosed as having a benign lesion. Five showed direct invasion from the primary carcinoma and another four were diagnosed as having mctastatic rib lesions, Benign rib lesions were also suspected in scvcral patients with multiple metastases. Lack of clinical significance of gallium-67 uptake in non-small cell lung cancer. Buccheri G, Vola F, Ferrigno D, Curcio A, Violante B. Departmenr of Amonio Carle Ilospiuzl, 12100 Cuneo. Eur J Respir Dis 1987;71:356- 61. To evaluate the clinical significance of tumor Ga-67 uptake, we studied 89 consecutive patients with a potentially resectable non-small cell lung cancer (NSCLC) by performing a whole body Ga-67 scan. For each scintigraphy, an overall Ga-67 accumulation index (T-N) and a volume independent index (T/Nr) were calculated. Both parameters wercrclated todiseaseextent, response to subsequenttreatmentand host survival. With the exception of the significant correlations of T-N to both stage of disease and survival - the higher the T-N, the more advanced the disease and the worse the prognosis no other relationship wasfound.Basedonthcsefindings, weconcludethat,inNSCLCatleast, gallium uptake is mainly dependent on tumor size and, therefore, of limited practical value. Serum pseudouridine as a biochemical marker in small cell lung cancer. Tamura S, Fujioka H, Nakano T, Hada T, Higashino K. Third Deparf- menI of Internul Medicine, Hyogo College of Medicine, Hyogo 663. Cancer Res 1987;47:6138-41. The serum lcvcl of pscudouridinc, primarily a degradation product of tRNA, was detcrmincd by high-performance liquid chromatography in 24 patients with small cell lung cancer (SCLC), 13 patients with non- SCLC with advanced stages, 15 patients with pulmonary infectious diseases, and 18 healthy controls. The mean serum pseudouridine concentration was significantly higher in the patients with SCLC I4.75 ??1.76 (SD) nmol/ml] than that in the patients with pulmonary infectious diseases (3.39 ?? 1.38 nmol/ml) or in healthy controls (2.21 ??0.78 nmol/ ml). The mean serum pseudouridine concentration in the patients with non-SCLC (4.07 ~0.95 nmol/ml) was significantly higher than that in healthy controls but not statistically different from that in the patients with pulmonary infectiousdiseases. Theserum pseudouridine level was elevated above the mean value plus 2 SD for the healthy subjects (3.77 nmol/ml) in 66.7% of all patients with SCLC including 3 of 8 (37.5%) with limited disease and 13 of 16 (81.3%) with extensive disease, and 53.8% oithcpaticnts with non-SCLC. Serumcarcinoembryonicantigen was elevated (>5 ng/ml) in 29.2% and serum neuron-specific enolase (>lOng/ml) in58,3%ofthecases withSCLC. In thepatients withSCLC followed up during chemotherapy, serum pseudouridinc levels changed considerably parallel with the changes in the clinical response. These findings indicate that serum pseudouridine may be a useful biochemical marker in the patients with SCLC. Clinical experience with tetracycline pleurodesis of malignant pleu- ral effusions. Sherman S, Grady KJ, Seidman JC. Pulmonary Division, Department of Internal Medicine, WilliamBeaumont Hospital, Royal Oak, MI 48072. South Med J 1987;80:716-9. Because many patients with malignant pleural effusions could sur- vive for months to years beyond its onset, definitive management must be safeandeffective. Chemical pleurodesis with tetracyclinehas gained general acceptance as the therapy of choice, even though no large series confirming this viewpoint has appeared in the literature. We reviewed 108 procedures involving tube thoracostomy and tetracycline pleurode- sis, and report a succes rate of 94.4% without serious complications. Considering all patients, 49% were symptom-free at three months, and 13% wcrc alive one year later. Several potentially important changes in technique have emerged since the initial description of this procedure. With adherence to meticulous technique, tetracycline pleurodesis pro- vidcs rapid, effective, and safe palliation of malignant pleural effusions. Gallium-67 scintigraphy and non-small-cell bronchogenic carci- noma: A quantitative in-vivo predictive assay? Lentle BC, Catz Z, Dierich HC, Scott JR, Hooper HR. Division of Nuclear Medicine, Vanvouver General Hospital, Vancouver, BC VSZ IM9. Can Med Assoc J 1987;137:815-7. Gallium-67 scintigraphy has been of limited use in detecting lung cancers and micrometastases. To study its potential for determining the aggressiveness of a cancer, we reviewed the charts of 44 patients with non-small-cell bronchogcnic carcinoma who had not been receiving treatment when 67Ga scintigraphy was performed. The mean length of survival for the 18 patients with low or little uptake of the tracer, corrected for tumour size, was 19.7 months, and for the 26 with high uptake 9.4 months (p < 0.01). Such in-vivo predictive assays may be a rational goal for tumour scintigraphy. Should patients with haemoptysis and a normal chest X-ray be bronchoscoped? Heaton RW. Department ofMedicine, Charing Cross Hospital. Fulham Palace Road, London W6 8RF. Postgrad Med J 1987:63:947-9. A review of bronchoscopic records over a 5 year period identified 4 1 patients who had undergone fibreoptic bronchoscopy after presenting with haemoptysis and a normal chest X-ray. Carcinoma of the bronchus was found in 4 patients (9.7%) and the procedure yielded a diagnosis in 8 of the 20 patients in whom a specific cause of their bleeding could be
Transcript of Serum pseudouridine as a biochemical marker in small cell lung cancer
S29
lin, D-10OOEerlin 39. Prax Klin Pneumol 1987;4l(Spec no):754-5. Basing on the favourable results obtained with palliative-sympto-
matic obliteration (pleurodesis) of malignant pleural effusions with tetracycline hydrochloride, we also used this therapy in 18 cases of malignant pericardial effusions - mostly caused by pleuropulmonary tumors. In 16 patients (88%) it was possible to stop the exudation within 2-l 1 days without recurrence during follow-up treatment. Since no complications worth mentioning were seen, we can consider drainage and intrapericardial instillation of tetracycline as the presently best possible method in the palliative treatment of this tumor complication.
Flare responses in small cell carcinoma of the lung. Cosolo W, Morstyn G, Arkles B, Zimet AS, Zalcberg JR. Deparfmenf ofMedical Oncology, Reparriation General Hospital, Wesr Heidelberg, Vie. 3081. Clin Nucl Med 1988;13:13-6.
Two cases of small cell carcinoma of the lung in which flare responses were demonstrated are discussed. Although the primary tumor and extraskeletal metastases responded to fist-line chemotherapy, bone scintigraphs performed 3 months after the start of treatment suggested tumor progression. Howcvcr, following repeat bone imaging and sub- sequent clinical evaluation, the interim scintigraphs appeared to repre- sent an unusual flare response, in which the activity of pre-existing hot spots increased and new lesions developed.
Scintigraphic diagnosis of rib lesions in patients with lung carci- noma. Matsumoto S. Shibuya H, Umchara I, Suzuki S. DepurfmenlofRadiol- ogy, TokyoMedicalandDental Universily. Bunkyo-ku, Tokyo 113. Clin Nucl Med 1987;12:960-2.
One hundred twenty-five patients with carcinoma of the lung re- ceived 17 1 pyrophosphate bone scans. Twenty-three ( 18%) of these 125 patients had abnormal uptake only in the ribs. Of these 23 patients, 14 (61%) were diagnosed as having a benign lesion. Five showed direct invasion from the primary carcinoma and another four were diagnosed as having mctastatic rib lesions, Benign rib lesions were also suspected in scvcral patients with multiple metastases.
Lack of clinical significance of gallium-67 uptake in non-small cell lung cancer. Buccheri G, Vola F, Ferrigno D, Curcio A, Violante B. Departmenr of Amonio Carle Ilospiuzl, 12100 Cuneo. Eur J Respir Dis 1987;71:356- 61.
To evaluate the clinical significance of tumor Ga-67 uptake, we studied 89 consecutive patients with a potentially resectable non-small cell lung cancer (NSCLC) by performing a whole body Ga-67 scan. For each scintigraphy, an overall Ga-67 accumulation index (T-N) and a volume independent index (T/Nr) were calculated. Both parameters wercrclated todiseaseextent, response to subsequenttreatmentand host survival. With the exception of the significant correlations of T-N to both stage of disease and survival - the higher the T-N, the more advanced the disease and the worse the prognosis no other relationship wasfound.Basedonthcsefindings, weconcludethat,inNSCLCatleast, gallium uptake is mainly dependent on tumor size and, therefore, of limited practical value.
Serum pseudouridine as a biochemical marker in small cell lung cancer. Tamura S, Fujioka H, Nakano T, Hada T, Higashino K. Third Deparf- menI of Internul Medicine, Hyogo College of Medicine, Hyogo 663. Cancer Res 1987;47:6138-41.
The serum lcvcl of pscudouridinc, primarily a degradation product of tRNA, was detcrmincd by high-performance liquid chromatography in
24 patients with small cell lung cancer (SCLC), 13 patients with non- SCLC with advanced stages, 15 patients with pulmonary infectious diseases, and 18 healthy controls. The mean serum pseudouridine concentration was significantly higher in the patients with SCLC I4.75 ??1.76 (SD) nmol/ml] than that in the patients with pulmonary infectious diseases (3.39 ??1.38 nmol/ml) or in healthy controls (2.21 ??0.78 nmol/ ml). The mean serum pseudouridine concentration in the patients with non-SCLC (4.07 ~0.95 nmol/ml) was significantly higher than that in healthy controls but not statistically different from that in the patients with pulmonary infectiousdiseases. Theserum pseudouridine level was elevated above the mean value plus 2 SD for the healthy subjects (3.77 nmol/ml) in 66.7% of all patients with SCLC including 3 of 8 (37.5%) with limited disease and 13 of 16 (81.3%) with extensive disease, and 53.8% oithcpaticnts with non-SCLC. Serumcarcinoembryonicantigen was elevated (>5 ng/ml) in 29.2% and serum neuron-specific enolase (>lOng/ml) in58,3%ofthecases withSCLC. In thepatients withSCLC followed up during chemotherapy, serum pseudouridinc levels changed considerably parallel with the changes in the clinical response. These findings indicate that serum pseudouridine may be a useful biochemical marker in the patients with SCLC.
Clinical experience with tetracycline pleurodesis of malignant pleu- ral effusions. Sherman S, Grady KJ, Seidman JC. Pulmonary Division, Department of Internal Medicine, William Beaumont Hospital, Royal Oak, MI 48072. South Med J 1987;80:716-9.
Because many patients with malignant pleural effusions could sur- vive for months to years beyond its onset, definitive management must be safeandeffective. Chemical pleurodesis with tetracyclinehas gained general acceptance as the therapy of choice, even though no large series confirming this viewpoint has appeared in the literature. We reviewed 108 procedures involving tube thoracostomy and tetracycline pleurode- sis, and report a succes rate of 94.4% without serious complications. Considering all patients, 49% were symptom-free at three months, and 13% wcrc alive one year later. Several potentially important changes in technique have emerged since the initial description of this procedure. With adherence to meticulous technique, tetracycline pleurodesis pro- vidcs rapid, effective, and safe palliation of malignant pleural effusions.
Gallium-67 scintigraphy and non-small-cell bronchogenic carci- noma: A quantitative in-vivo predictive assay? Lentle BC, Catz Z, Dierich HC, Scott JR, Hooper HR. Division of Nuclear Medicine, Vanvouver General Hospital, Vancouver, BC VSZ IM9. Can Med Assoc J 1987;137:815-7.
Gallium-67 scintigraphy has been of limited use in detecting lung cancers and micrometastases. To study its potential for determining the aggressiveness of a cancer, we reviewed the charts of 44 patients with non-small-cell bronchogcnic carcinoma who had not been receiving treatment when 67Ga scintigraphy was performed. The mean length of survival for the 18 patients with low or little uptake of the tracer, corrected for tumour size, was 19.7 months, and for the 26 with high uptake 9.4 months (p < 0.01). Such in-vivo predictive assays may be a rational goal for tumour scintigraphy.
Should patients with haemoptysis and a normal chest X-ray be bronchoscoped? Heaton RW. Department ofMedicine, Charing Cross Hospital. Fulham Palace Road, London W6 8RF. Postgrad Med J 1987:63:947-9.
A review of bronchoscopic records over a 5 year period identified 4 1 patients who had undergone fibreoptic bronchoscopy after presenting with haemoptysis and a normal chest X-ray. Carcinoma of the bronchus was found in 4 patients (9.7%) and the procedure yielded a diagnosis in 8 of the 20 patients in whom a specific cause of their bleeding could be
